Literature DB >> 32617381

Factors Associated With Testing for Hepatitis C Infections Among a Commercially Insured Population of Persons With HIV, United States 2008-2016.

Hope King1, Lara Bull-Otterson2, Karen W Hoover3, Huang Ya-Lin A Huang3, Weiming Zhu3, William Thompson1.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is an important public health problem among people with HIV. People with HIV who are coinfected with HCV infection are at increased risk for cirrhosis, liver failure, and hepatitis C-related mortality; as such, national guidelines recommend that persons with HIV be tested for HCV infection.
METHODS: Data from the 2003-2017 IBM Watson Health MarketScan database were used for this study. We used diagnostic, procedural, and drug codes to identify patients with ≥1 inpatient or outpatient medical claim of HIV diagnosis. Patients with prior HIV or hepatitis C diagnoses were excluded. We calculated hepatitis C testing rates among newly diagnosed HIV-infected persons within 12 months of the initial HIV diagnosis date (January 1, 2008-December 31, 2016). We used Poisson regression to identify the factors associated with hepatitis C testing. Lastly, we assessed hepatitis C testing trends using the Cochran-Armitage test.
RESULTS: The prevalence of testing for hepatitis C in newly identified persons with HIV (n = 46 277) was 50% within 12 months of the index HIV diagnosis. From 2008 to 2017, the testing rate increased by 13%. Significant predictors of hepatitis C testing were age, sex, and urbanicity. Women with HIV were less likely to have been tested compared with men (relative risk, 0.79; 95% CI, 0.77-0.81). Only 40% of patients between 50 and 59 years of age were tested for hepatitis C within 12 months of the index HIV diagnosis, while 56% of persons with HIV aged 20-29 years were tested for hepatitis C.
CONCLUSIONS: Overall, 50% of newly diagnosed HIV patients were tested for hepatitis C within 12 months of HIV diagnosis. Although there were increases in hepatitis C testing rates over the study period, there were missed opportunities to detect HCV infection among people newly diagnosed with HIV. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.

Entities:  

Keywords:  HIV; co-infection; hepatitis C; hepatitis C virus (HCV) infection

Year:  2020        PMID: 32617381      PMCID: PMC7320833          DOI: 10.1093/ofid/ofaa222

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


  29 in total

1.  1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1999-08-20

2.  Hepatitis C Antibody Testing in a Commercially Insured Population, 2005-2014.

Authors:  Cheryl J Isenhour; Susan H Hariri; Craig M Hales; Claudia J Vellozzi
Journal:  Am J Prev Med       Date:  2017-02-01       Impact factor: 5.043

3.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

4.  Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States and Kentucky, 2011-2014.

Authors:  Alaya Koneru; Noele Nelson; Susan Hariri; Lauren Canary; Kathy J Sanders; Justine F Maxwell; Xiaohua Huang; John A D Leake; John W Ward; Claudia Vellozzi
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-07-22       Impact factor: 17.586

5.  Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.

Authors:  Marina B Klein; Keri N Althoff; Yuezhou Jing; Bryan Lau; Mari Kitahata; Vincent Lo Re; Gregory D Kirk; Mark Hull; H Nina Kim; Giada Sebastiani; Erica E M Moodie; Michael J Silverberg; Timothy R Sterling; Jennifer E Thorne; Angela Cescon; Sonia Napravnik; Joe Eron; M John Gill; Amy Justice; Marion G Peters; James J Goedert; Angel Mayor; Chloe L Thio; Edward R Cachay; Richard Moore
Journal:  Clin Infect Dis       Date:  2016-08-09       Impact factor: 9.079

Review 6.  An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection.

Authors:  Arthur Y Kim; Shauna Onofrey; Daniel R Church
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

7.  Causes of death and characteristics of decedents with viral hepatitis, United States, 2010.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

8.  Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2012-11-09

Review 9.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.

Authors:  Lucy Platt; Philippa Easterbrook; Erin Gower; Bethan McDonald; Keith Sabin; Catherine McGowan; Irini Yanny; Homie Razavi; Peter Vickerman
Journal:  Lancet Infect Dis       Date:  2016-02-25       Impact factor: 25.071

10.  Hepatitis C Screening in People With Human Immunodeficiency Virus: Lessons Learned From Syphilis Screening.

Authors:  Alysse G Wurcel; Daniel D Chen; Rosemary E Fitzpatrick; Paula E Grasberger; Caleb H Kirshner; Jordan E Anderson; Kenneth K H Chui; Tamsin A Knox
Journal:  Open Forum Infect Dis       Date:  2016-02-12       Impact factor: 3.835

View more
  1 in total

1.  Self-reported hepatitis C(HCV) testing among people living with human immunodeficiency virus (PLWH).

Authors:  Mustapha Thaim Buya Kamara; Veronica L Richards; Charurut Somboonwit; Haesuk Park; Nana Ayegua Hagan Seneadza; Zhou Zhi; Dushyantha Jayaweera; Emmanuel Thomas; Robert L Cook
Journal:  Heliyon       Date:  2021-08-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.